|
|
 |
|
Viewing report
|
|
|
|
Nucleic Acid Drug Delivery Technologies: Players, products & prospects to 2018 (Volume III)
Espicom Business Intelligence Ltd, June 2009, Pages: 110
The nucleic acid delivery market is maturing with over 1,450 clinical trials underway worldwide. The majority of these are in early clinical development (approximately 60%) with just over 3% in Phase III trials. Our analysis indicates that up to 35 novel nucleic acid products could reach the market within our forecasting period (2008-2018). However the harsh economic environment may force companies to place promising drugs on hold as they focus on lead projects rather than multiple programmes. To date, only a handful of nucleic acid-based products have been approved for human prescription and these products rely on delivery technologies in one shape or form. We estimate the nucleic acid market was worth just over US$80 million globally in 2008.
By 2018 we anticipate the nucleic acid technology market will have matured as many of the late-stage clinical programmes come to fruition and drug delivery companies continue to overcome issues surrounding its safety and efficiency. The development of nucleic acid delivery systems will help to improve specificity whilst the development of novel polymers and lipopolymer complexes will help to carry larger DNA payloads in order to target cells and make multigene targeting a reality. We forecast that nucleic acid products in development from 11 key companies could generate additional sales of nearly US$2.3 billion by 2018. These products utilise a range of delivery platforms including viral to non-viral delivery systems, and cover gene therapies, gene agents and DNA vaccines for a variety of targets including cancer, cardiovascular and infectious diseases.
Catalysts for change
Improvements in our understanding into the underlying genetic causes of disease as well as the uptake of new mechanisms of modulating DNA such as RNA interference which will help to fuel market growth.
The development of a new generation of DNA vaccines that will provoke strong immunogenic responses and will help to determine whether this has been a sound investment for the pharma industry.
Launch of the first siRNA-based therapeutics (although progress has been dampened following the recent termination of Opko Health’s leading eye treatment at the Phase III development stage). We anticipate companies will pursue other conditions such as infectious diseases and cancer where robust preclinical studies have already been performed and where drug delivery platforms have been adopted rather than the use of naked siRNAs.
This report is part of a major new 4-volume strategic analysis
Drug Delivery Technologies:
Players, Products & Prospects to 2018
Focusing on the sectors that are driving growth
VOLUME I
CONTROLLED- RELEASE
VOLUME II
NANOTECHNOLOGY
VOLUME III
NUCLEIC ACID DELIVERY
VOLUME IV
TARGETED DELIVERY
Customers who bought this item also bought
Targeted Drug Delivery Technologies: Players, products & prospects to 2018 (Volume IV)
Nanotechnology: Players, products & prospects to 2018 (Volume II)
Drug Delivery in Cancer - Technologies, Markets and Companies
Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships
Drug Delivery Technologies: Players, products & prospects to 2018
Controlled-release: Players, products & prospects to 2018 (Volume I)
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Transdermal Drug Delivery - Technologies, Markets, and Companies
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
Drug Delivery Technology - Revolutionizing Cardiovascular Treatment
|
|
|
|
